Lonnel Coats Lexicon Pharmaceuticals, Inc. (LXRX) insider trading activity

Lonnel Coats is Chief Executive Officer of LEXICON PHARMACEUTICALS, INC.. Currently has a direct ownership of 1.1 Million shares of LXRX, which is worth approximately $779,628. The most recent transaction as insider was on Feb 28, 2024, when has been sold 61,371 shares (Common Stock) at a price of $2.62 per share, resulting in proceeds of $160,792. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.1M

0% 3M change

20.09% 12M change

Total Value Held $779,628

LONNEL COATS Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 28 2024	SELL Payment of exercise price or tax liability	$160,792 $2.62 p/Share	61,371 Reduced 5.29%	1,098,068 Common Stock
Feb 28 2024	BUY Exercise of conversion of derivative security	-	245,080 Added 17.45%	1,159,439 Common Stock
Nov 16 2023	BUY Open market or private purchase	$94,500 $1.05 p/Share	90,000 Added 8.96%	914,359 Common Stock
Nov 10 2023	BUY Open market or private purchase	$10,100 $1.01 p/Share	10,000 Added 1.2%	824,359 Common Stock
Jun 29 2023	BUY Open market or private purchase	$21,600 $2.16 p/Share	10,000 Added 1.21%	814,359 Common Stock
Jun 26 2023	BUY Open market or private purchase	$21,800 $2.18 p/Share	10,000 Added 1.23%	804,359 Common Stock
Jun 23 2023	BUY Open market or private purchase	$25,000 $2.5 p/Share	10,000 Added 1.24%	794,359 Common Stock
Jun 22 2023	BUY Open market or private purchase	$92,400 $2.31 p/Share	40,000 Added 4.85%	784,359 Common Stock
Feb 28 2023	SELL Payment of exercise price or tax liability	$110,607 $2.17 p/Share	50,971 Reduced 6.41%	744,359 Common Stock
Feb 28 2023	BUY Exercise of conversion of derivative security	-	209,327 Added 20.84%	795,330 Common Stock
Feb 28 2022	SELL Payment of exercise price or tax liability	$136,951 $2.85 p/Share	48,053 Reduced 7.58%	586,003 Common Stock
Feb 28 2022	BUY Exercise of conversion of derivative security	-	197,343 Added 23.74%	634,056 Common Stock
Feb 28 2021	SELL Payment of exercise price or tax liability	$395,723 $7.19 p/Share	55,038 Reduced 11.19%	436,713 Common Stock
Feb 28 2021	BUY Exercise of conversion of derivative security	-	192,885 Added 28.17%	491,751 Common Stock

Also insider at

BPMC

Blueprint Medicines Corp Healthcare

VERV

Verve Therapeutics, Inc. Healthcare

Lonnel Coats

Chief Executive Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LXRX shares.

Notify only if

Value

Insider Trading

Get notified when an Lexicon Pharmaceuticals, Inc. insider buys or sells LXRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to LEXICON PHARMACEUTICALS, INC.

Track Activities on LXRX

Account